NNNatasha S. Namjoshi

Natasha S. Namjoshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natasha S. Namjoshi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Elysia Alvarez

    Division of Pediatric Hematology/Oncology Department of Pediatrics School of Medicine University of California Davis Davis California USA

    1 shared publication
  • Jennifer L. Rosenthal

    Division of Pediatric Hospital Medicine, University of California Davis School of Medicine, Sacramento, CA, USA

    1 shared publication
  • Jong H. Chung

    Division of Pediatric Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA

    1 shared publication
  • Lena E. Winestone

    Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA

    1 shared publication
  • Lori Muffly

    Department of Medicine Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA

    1 shared publication
  • Marcio H. Malogolowkin

    Division of Pediatric Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA

    1 shared publication

Latest Publications

  • Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis

    by Natasha S. Namjoshi, Theresa H. M. Keegan, Qian C. Li, Jong H. Chung, Jennifer L. Rosenthal, Lena E. Winestone, Lori Muffly, Marcio H. Malogolowkin, Elysia M. Alvarez

    Treatment-related toxicities (TRTs) are a potential cause of survival disparities in patients with acute lymphoblastic leukemia (ALL). We aimed to identify the most frequent TRTs associated with hospitalizations at a population level in children, adolescents and young adults (AYAs). We used the California Cancer Registry linked to a statewide hospital discharge database to identify children and AYAs with TRTs within 3 years of diagnosis. We assessed the frequency of TRTs, length of stay (LOS), admission rates associated with TRTs and TRTs impact on survival. Febrile neutropenia, hypertension, and thrombocytopenia were the most common TRTs for both children and AYAs. AYAs had longer median LOS compared to children for most toxicities. AYAs at non-specialized cancer centers (SCCs) had higher frequency of admissions associated with TRTs compared to non-SCC. Cardiovascular, respiratory, gastrointestinal, renal, and infectious TRTs were associated with worse survival. This study demonstrates the burden of TRTs in patients with ALL.